OCI-LY19 Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | OCI-Ly19 is a human B-cell lymphoma cell line derived from the malignant lymph node of a patient with diffuse large B-cell lymphoma (DLBCL), a common and aggressive subtype of non-Hodgkin lymphoma. This cell line serves as a valuable tool for investigating the molecular mechanisms underlying DLBCL pathogenesis, including aberrant B-cell receptor (BCR) signaling, dysregulation of transcription factors, and genetic alterations driving tumor progression. OCI-Ly19 is frequently used in studies aimed at understanding DLBCL biology and developing targeted therapeutic strategies. OCI-Ly19 cells exhibit typical B-cell morphology and grow in suspension under standard culture conditions. The cell line is characterized by chromosomal abnormalities and genetic alterations commonly associated with DLBCL, including those affecting the MYC oncogene and BCL-2 family members. These features make OCI-Ly19 an important model for studying oncogenic signaling pathways, such as the PI3K/AKT/mTOR and NF-κB pathways, which are critical for B-cell survival and proliferation in lymphoma. In addition, OCI-Ly19 cells express surface markers characteristic of mature B cells, making them suitable for exploring antigen receptor signaling and immune evasion mechanisms in lymphoma. OCI-Ly19 is widely used in preclinical research to evaluate the efficacy of chemotherapeutic agents, monoclonal antibodies (e.g., anti-CD20 therapies), and small-molecule inhibitors targeting key signaling pathways. The cell line is also employed in drug resistance studies, particularly in the context of understanding mechanisms of relapse in DLBCL and identifying strategies to overcome treatment resistance. Its well-characterized genomic profile and relevance to DLBCL biology make OCI-Ly19 an indispensable resource for lymphoma research and therapeutic development. |
|---|---|
| Organism | Human |
| Tissue | Bone |
| Disease | B cell lymphoma |
| Synonyms | OCI-LY19, OCI-LY-19, OCI-Ly 19, OCI Ly19, OCILY-19, OCILY19, OCILy19, Ly19, LY19 |
Characteristics
| Age | 25 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Single, round cells |
| Growth properties | Suspension |
Regulatory Data
| Citation | OCI-LY19 (Cytion catalog number 305610) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1878 |
Biomolecular Data
| Antigen expression | CD3-, CD10+, CD13-, CD19+, CD20(+), CD34(+), CD37-, CD38+, CD80-, CD138-, HLA-DR(+), sIgG+, sIgM-, cIgkappa-, sIglambda+ |
|---|---|
| Viruses | PCR: EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-1/2 -, MLV -, SMRV - |
| Mutational profile | Mutation: NRAS, p.Gln61Lys (c.181C>A), Heterozygous |
| Karyotype | Human hyperdiploid karyotype with 4% polyploidy - 48(46-52)<2n>X, -X, +6, +6, +8, t(4;8)(q3?2;q?24), del(6)(q15)x2, r(8)(??), t(14;18)(q32;q21), add(18)(q23) - carries t(14;18) effecting IGH-BCL2 juxtaposition |
Handling
| Culture Medium | EMEM (MEM Eagle), w: 2 mM L-Glutamine, w: 2.2 g/L NaHCO3, w: EBSS (Cytion article number 820100a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Doubling time | 40 hours |
| Seeding density | 3 x 106 cells/ml |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305610-031125 | Certificate of Analysis | 05. Dec. 2025 | 305610 |